Cantor Fitzgerald Forecasts Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Zura Bio in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($0.40) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

Several other equities analysts have also recently issued reports on the company. Leerink Partners assumed coverage on Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. Chardan Capital lowered their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $15.80.

Zura Bio Price Performance

NASDAQ ZURA opened at $1.79 on Thursday. Zura Bio has a one year low of $1.74 and a one year high of $6.35. The firm has a 50 day simple moving average of $2.52 and a 200-day simple moving average of $3.47.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12).

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC raised its stake in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after buying an additional 876,000 shares in the last quarter. Braidwell LP purchased a new stake in shares of Zura Bio during the 3rd quarter worth $10,040,000. Point72 Asset Management L.P. acquired a new position in shares of Zura Bio during the 2nd quarter worth $8,446,000. Geode Capital Management LLC increased its holdings in shares of Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after purchasing an additional 377,545 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Zura Bio in the third quarter valued at about $2,999,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Insiders Place Their Bets

In other news, Director Parvinder Thiara sold 1,001,633 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.10% of the stock is currently owned by insiders.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.